Description: Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Home Page: www.boltbio.com
BOLT Technical Analysis
900 Chesapeake Drive
Redwood City,
CA
94063
United States
Phone:
650 665 9295
Officers
| Name | Title |
|---|---|
| Dr. Randall C. Schatzman Ph.D. | CEO & Director |
| Dr. Edgar G. Engleman M.D. | Founder & Independent Director |
| Mr. William P. Quinn | CFO & Sec. |
| Mr. Grant Yonehiro C.F.A., M.B.A. | Chief Bus. Officer |
| Dr. Edith A. Perez M.D. | Chief Medical Officer |
| Ms. Karen L. Bergman | VP of Communications & Investor Relations |
| Mr. Wesley Burwell | VP & Head of HR |
| Dr. Nathan Ihle Ph.D. | Sr. VP of Pharmaceutical Operations |
| Mr. Bruce Hug M.D., Ph.D. | Sr. VP of Clinical Devel. & Translational Medicine |
| Dr. Ming Yin Ph.D. | VP & Head of Biometrics |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2698 |
| Price-to-Sales TTM: | 10.301 |
| IPO Date: | 2021-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 91 |